McKesson Q2 FY27: where the revenue came from and where it went
The whole income statement of McKesson for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 4, 2026
Revenue$110.96B
+8% year over year
Gross profit$3.96B
4% margin
Operating profit$1.60B
1% margin
Net profit$1.22B
1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 110.96 | 100% | +8% |
| North american | 91.36 | 82% | +6% |
| Oncology & multispecialty | 14.98 | 14% | +24% |
| Medical-Surgical | 3.10 | 3% | +5% |
| Prescription technology | 1.52 | 1% | +10% |
| Cost of revenue | −107.00 | 96% | |
| Gross profit | 3.96 | 4% margin | |
| SG&A | −2.27 | 2% | +0pp |
| Other | −0.08 | 0% | +0pp |
| Operating profit | 1.60 | 1% margin | +0pp |
| Interest & other costs | −0.12 | ||
| Tax | −0.27 | ||
| Net profit | 1.22 | 1% margin | +0pp |
16 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest